ESR1 and breast cancer: More importantly, survival curves from ER+ breast cancer patients without tamoxifen treatment were independent of HOXA5 expression as compared to survival curves of patients who received tamoxifen treatment, which demonstrated that a higher expression of HOXA5 resulted in a poorer overall survival (Fig. 1C).